Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
Reaction mass of copper complex of [(2,6-difluoroheterocycl-4-yl)amino]hydroxy{[2-hydroxy-3-sulfonato-5-(vinylsulfonyl)phenyl]diazenyl}naphthalene sulfonic acid, dialkali salt and copper complex of [(2,6-difluoroheterocycl-4-yl)amino]-hydroxy{[2-hydroxy-3-sulfonato-5-{[2-(sulfonatooxy)ethyl]sulfonyl}phenyl]diazenyl}naphthalene sulfonic acid, trialkali salt
EC number: 479-550-2 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Repeated administration ofReactive RedF00-0124 at a dose levels of 50 or 200mg/kg body weight and day did not cause any adverse substance related alterations.
With regard to the present study the 'No Observed Adverse Effect Level' (NOAEL) is 200 mg/kgbody weight, and the 'No Observed Effect Level' (NOEL) is 50 mg/kg body weight per day.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2003-04-14 to 2003-07-31
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Qualifier:
- according to guideline
- Guideline:
- other: US EPA OPPTS 870.3050
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Winkelmann GmbH Gartenstrasse 27 D-33178 Borchen
- Age at study initiation: approximately 6 weeks
- Housing: In transparent macrolon cages (type IV) on soft wood granulate in an air-conditioned rooms, 5 animals per cage, separated according to sex
- Diet (e.g. ad libitum): ssniff R/M-H (V 1534) ad libitum, except for the period in which the animals were kept in diuresis cages
- Water (e.g. ad libitum): Tap water in plastic bottles ad libitum, except for the period in which the animals were kept in diuresis cages
- Acclimation period: at least five days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3 °C
- Humidity (%): 50 ± 20 %
- Photoperiod (hrs dark / hrs light): 12 hours light / dark cycle - Route of administration:
- oral: gavage
- Vehicle:
- water
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- First and last week of treatment phase
- Duration of treatment / exposure:
- 28
- Frequency of treatment:
- daily
- Dose / conc.:
- 50 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 200 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 800 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- Male: 10 animals at 0 mg/kg bw/day
(5 main group, 5 recovery group)
Male: 5 animals at 50 mg/kg bw/day
Male: 5 animals at 200 mg/kg bw/day
Male: 10 animals at 800 mg/kg bw/day (5 main group, 5 recovery group)
Female: 10 animals at 0 mg/kg bw/day (5 main group, 5 recovery group)
Female: 5 animals at 50 mg/kg bw/day
Female: 5 animals at 200 mg/kg bw/day
Female: 10 animals at 800 mg/kg bw/day (5 main group, 5 recovery group) - Control animals:
- yes
- Details on study design:
- - Dose selection rationale:
An acute oral toxicity testing of Reaktiv Rot F00-0124 determined the median LD50 is above 2000 mg/kg bw in male and female rats. A dose range finding study in 3 male and 3 female rats receiving Reaktiv Rot F00-0124 at doses of 400 and 800 mg/kg bw/day over 14 days was conducted. Neither deaths nor clinical symptoms occurred. Based on these results, dose levels of 0, 50, 200 and 800 mg/kg body weight per day were selected for the present study. - Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Survival control of the animals was examined twice daily (on weekends and public holidays once daily).
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Individual clinical observations were observed once daily
BODY WEIGHT: Yes
- Time schedule for examinations: determinated before the start of the study and then twice weekly throughout the study
FOOD CONSUMPTION AND COMPOUND INTAKE:
- Food consumption for each animal determined: Yes - Food consumption was determined continuously (two times per week)
HAEMATOLOGY: Yes
- Time schedule for collection of blood: At the termination of the study and after the recovery period
- Anaesthetic used for blood collection: Yes - Ketamine-Hydrochloride + Xylazine
- Animals fasted: No
- How many animals: al: Erythrocyte counts, Heinz Body Counts, Hematocrit, Hemoglobin, Mean corpuscular hemoglobin, Mean corpuscular hemoglobin concentration, Mean corpuscular volume, Reticulocyte counts, Differential leukocyte counts, Leukocyte counts, Coagulation time, Thrombocyte counts
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: After blood sampling for hematological testing, the animals were killed by section of the vena cava cranialis in deep narcosis and exsanguinated
- Animals fasted: No
- How many animals: all animals
- Parameters checked: gamma-Glutamyltranspeptidase, Alanine Aminotransferase, Albumin, Albumin / Globulin ratio, Alkaline Phosphatase, Aspartate Aminotransferase, Bilirubin total, Calcium, Chloride Cholesterol, Creatinine, Globulin, Glucose, Inorganic Phosphorous, Potassium, Sodium, Total Protein, Triglycerides, Urea, Uric Acid
URINALYSIS: Yes
- Time schedule for collection of urine: a few days before termination of the study
- urine was collected in diuresis cages (overnight from day 22 to day 23)
- Animals fasted: Yes
- Parameters checked: Appearance, Bilirubin, Blood, Color, Glucose, Ketone bodies, Microscopic Examination, pH, Protein, Urobilinogen
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: Once before the first treatment and weekly thereafter detailed clinical observations were performed in all animals outside the home cage in a standard arena
- Battery of functions tested: changes in skin, fur, eyes, mucous membranes, occurrence of secretions and excretions and autonomic activity such as lacrimation, salivation, nasal discharge, piloerection, pupil size, and unusual respiratory pattern. Changes in gait, posture, and response to handling as well as the presence of clonic or tonic movements, tremor, and any other abnormal motor movements (such as excessive grooming, repetitive circling or other stereotypes) or bizarre behavior (e.g. self-mutilation, walking backwards) were also recorded. In addition, defecation and urination were evaluated. At the termination of the study sensory reactivity to stimuli of different types (auditory, visual, and proprioceptive) was evaluated including startle reflex (click response), response to approach with the finger to the nose of the animal, and righting reflex. The presence and absence of pupillary constriction was assessed using a pen flashlight directed into the eye. Assessments of motor function were performed including measurement of motor activity, and forelimb and hindlimb grip strength. The animals were evaluated for motor activity during a 60-minute period in an 16-station automated motor activity monitoring device. Activity counts were recorded by the interruption of photocells in 3-minute-intervals to give a total of 20 intervals. Fore- and hindlimb grip strength were measured by a strain gauge device - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
- After exsanguination, all animals were necropsied and checked for macroscopically visible abnormalities. The autopsy included macroscopic examination of the skin, orifices, eyes, teeth, oral mucosa and internal organs
- Endotracheal fixation of the lungs, Adrenals, Brain, Epididymides, Heart, Kidneys, Liver, Spleen, Testes, Thymus
HISTOPATHOLOGY: Yes
- Histopathological examinations were carried out of the control and high dose animals
- Adrenals, Bone marrow / sternum, Brain with medulla oblongata, Epididymides, Heart, Small Intestine jejunum, Large Intestine colon, Kidneys, Liver, Lungs, Lymph nodes mandibular, Lymph nodes iliac, Nerve sciatic nerve, Ovaries, Prostate, Seminal vesicle, Spinal cord cervical, Spleen, Stomach, Testes, Thymus, Thyroid gland with parathyroids, Trachea, Urinary bladder, Uterus, All other gross lesions - Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Control and low dose group showed no clinical observations.
Animals from the mid dose group showed black discolored feces from day 13 up to the end of the treatment period (study day 29). One female animal of the mid dose group showed stilted gait and squatting posture from day 23 up to day 29, another female animal of this group showed squatting posture from day 27 up to study day 29 (end of treatment period). Due to the fact that only two animals of this dose group showed this finding and in the absence of any other relevant alterations in the mid dose group, these alterations are not considered as adverse findings as the health status is not affected.
Animals in the high dose group high dose showed black discolored feces from day 2 up to the end of the treatment period. Seven of ten males showed squatting posture and/or stilted gait from day 26/27 up to the end of the treatment period. These symptoms were also noted in all females of the high dose group starting in the last study week and lasting up to the end of treatment or even day 31 (three females of the recovery group). - Mortality:
- no mortality observed
- Description (incidence):
- No deaths occurred throughout the study.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Body weight gains of the females treated with 800 mg/kg bw. per day (high dose) decreased within the treatment period (mean decrease day 1 to 29 : 14 %), while no alterations were noted in the other groups.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Organ weight analysis revealed no relevant alterations in all dose groups except of slightly decreased absolute liver weights in female animals treated with 800 mg/kg per day after the treatment period, which normalized after the recovery period.
No relevant changes in organ weights were observed in all dose groups after the treatment and recovery period. - Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Animals from the low dose group showed no macroscopic alterations. Two males from the mid dose group showed small testes and epididymides, which is considered as incidental finding in the absence of any macroscopic or microscopic observations in these organs in the high dose group.
In the high dose group three females showed dark brown discolored kidneys and two of them additionally black spleens after the treatment period. Black discolored spleens were also observed in three females of the high dose group after the recovery period.This is due to the staining effect of the dye - Neuropathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- Clinical observations:
Control and low dose group showed no clinical observations. Animals of the mid dose group showed black discolored feces from day 13 up to the end of the treatment period. One female of the mid dose group showed stilted gait and squatting posturefrom day 23 up tp day 29, another female
from this dose group showed squatting posture from day 27 up to study day 29. Animals in the high dose group showed black discolored feces from day 2 up to the end of the treatment period. Seven of ten males showed squatting posture and/or stilted gait from day 26/27 up to the end of the treatment period. These symptoms were also noted in all females of the high dose group starting i the last study week and lasting up to day 29 or 31. No other symptoms and no opacitiy of the refracting media of the eyes,changes of the oral mucosa, or impairments of dental growth were observed in all groups. Neurotoxicological measurements showed no substance related effect.Body weight gains were not influenced by the administration of the test compound in the low and mid dose group and in males of the high dose group. Female animals of the high dose group showed a slightly reduced body weight gain during the treatment period. Food consumption remained uneffected by the administration of the test compound throughout the study in all dose groups.
Body weight and weight gain:
Body weight gains were not influenced by the administration of the test compound in the low and mid dose group and in males of the high dose group. Female animals of the high dose group showed slightly reduced body weight gains (mean reduction in body weight gain between day 1 and 29: 14 %) during the treatment period.
Effects in organs:
Organ weight analysis revealed no relevant alterations in all dose group except of slightly decreased absolute liver wights in female animals treated with 800 mg/kg per day after the treatment period which normalized after the recovery period. Animals from the low dose group showed no macroscopic alterations. In the high dose group three females showed dark brown discolored kidneys and two of them additionally black spleens after the treatment period. Black discolored spleens were also observed in three females of the high dose group after the recovery period. No test compound related histopatological findings were observed.
Gross pathology:
Animals from the low dose group showed no macroscopic alterations. Two males from the mid dose group showed small testes and epididymides, which is considered as incidental finding in the absence of any macroscopic or microscopic observations in these organs in the high dose group. In the high dose group three females showed dark brown discolored kidneys and two of them additionally black spleens after the treatment period. Black discolored spleens were also observed in three females of the high dose group after the recovery period. - Dose descriptor:
- NOEL
- Effect level:
- 50 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical signs
- gross pathology
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 200 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical signs
- Dose descriptor:
- LOAEL
- Effect level:
- 800 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical signs
- Critical effects observed:
- no
- Conclusions:
- Under the conditions of this study, repeated administration of Reaktiv Rot F00-0124 at dose levels of 50 or 200 mg/kg/d did not cause any adverse substance related alterations.
- Executive summary:
In a subacute toxicity study, Reactive Red F00-0124 was administered to 5 Sprague Dawley rats/sex/dose, with an additional 5/sex for the recovery group in the control and high dose group. The test substance was administered via oral gavage in deionized water at dose levels of 0, 50, 200 and 800 mg/kg bw/day.
The test item was well tolerated and resulted in no deaths or severe clinical symptoms. Neurotoxicological examination, hematology and clinical chemistry values as well as urinalysis and histopathological investigation showed no substance related or biologically relevant alterations in all dose groups.
Animals in the high dose group (800 mg/(kg/d) showed squatting posture and/or stilted gait at the end of the treatment period. Female animals of the high dose group showed additionally slightly reduced body weight gains during the treatment period (14 %), slightly decreased absolute liver weights. However, these changes were reversible and normalized after the recovery period. The NOAEL is 200 mg/kg bw/day, the LOAEL is 800 mg/kg/day.
This subacute toxicity study in the rat is acceptable and satisfies the guideline requirement for a subacute oral study (OECD 407) in rats.
Reference
Mean body weight gains [g] throughout the study
Treatment group
[mg/kg bw] |
Control |
50 mg/kg |
200 mg/kg |
800 mg/kg |
||||
males |
females |
males |
femals |
males |
females |
males |
females |
|
day 1 to day 29 |
121.2 |
76.0 |
127.6 |
76.4 |
115.6 |
73.6 |
132.5 |
65.4 |
day 29 to day 43 |
28.6 |
12.6 |
- |
- |
- |
- |
32.0 |
20.0 |
Female animals of the high dose group showed slightly reduced body weight gains (mean reduction in body weight gain between day 1 and 29: 14 %) during the treatment period.
Mean food consumption [g/kg bw/day] throughout the study
Treatment group
[mg/kg bw ] |
Control |
50 mg/kg |
200 mg/kg |
800 mg/kg |
||||
males |
females |
males |
females |
males |
females |
males |
females |
|
day 1 to day 29 |
87.95 |
88.97 |
88.28 |
88.69 |
88.11 |
90.17 |
87.94 |
88.53 |
day 29 to day 43 |
67.59 |
70.59 |
- |
- |
- |
- |
66.54 |
75.03 |
Food consumption remained unaffected by the administration of the test compound throughout the study in all dose groups.
Changes in absolute organ weights (final value day 29)
Parameter |
1 |
2 |
3 |
4 |
1 |
2 |
3 |
4 |
Liver |
9.884 |
10.062 |
9.178 |
10.776 |
7.308 |
7.882 |
7.688 |
6.182- |
Organ weight analysis revealed no relevant alterations in all dose groups except of slightly decreased absolute liver weights in female animals treated with 800 mg/kg per day after the treatment period, which normalized after the recovery period.
Changes in relative organ weights (final value day 29)
Parameter |
1 |
2 |
3 |
4 |
1 |
2 |
3 |
4 |
Spleen (% of bw.) |
0.24725 |
0.26654 |
0.26039 |
0.26453 |
0.29630 |
0.32113+ |
0.33153+ |
0.35142+ |
Relative liver weights were slightly but not but statistically significantly decreased after the treatment period in females of the high dose group, but the mean value (3.2765) correspond to the control value after the recovery period (3.2828). Additionally, relative spleen weights were slightly increased in females, but exceeded the historical control data range only marginally in the high dose group after the treatment period. In the low dose group none of the individual values was outside the historical range, while in the mid dose group only one female (No. 46) showed a relative spleen weight slightly outside the control range. Therefore alterations in relative spleen weights in the low and mid dose group are not considered as relevant or substance related findings. No significant alterations were observed after the recovery period.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 200 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
In a subacute toxicity study, Reactive Red F00-0124 was administered to 5 SD rats/sex, with an additional 5/sex for the recovery group in the control and high dose group. The test substance was administered via oral gavage in deionized water at dose levels of 0, 50, 200 and 800 mg/kg bw/day.
The test item was well tolerated and resulted in no deaths or severe clinical symptoms. Neurotoxicological examination, hematology and clinical chemistry values as well as urinalysis and histopathological investigation showed no substance related or biologically relevant alterations in all dose groups.
Animals in the high dose group showed black discolored feces from day 2 up to the end of the treatment period. Seven of ten males showed squatting posture and/or stilted gait from day 26/27 up to the end of the treatment period. These symptoms were also noted in all females of this dose group starting in the last study week and lasting up to the end of treatment or even day 31 (three females from the recovery group). Female animals of the high dose group showed additionally slightly reduced body weight gains during the treatment period (14 %), slightly decreased absolute liver weights as well as slightly increased relative spleen weights. However, these changes were reversible and normalized after the recovery period. Additionally, individual females of the high dose group showed dark brown discolored kidneys and black spleens after the treatment period. Black discolored spleens were also observed in three females of the high dose group after the recovery period. However, no correlating microscopic findings were observed. The low dose and mid dose group showed neither changes in body weight gain nor relevant macroscopic findings or relevant changes in organ weights. Relative spleen weights were slightly increased compared with the control, but none of the individual values was outside the historical range in the low dose group, and only one female in the mid dose group showed a relative spleen weight slightly outside the control range. Therefore, alterations in relative spleen weights in the low and mid dose group are not considered as relevant or substance related findings.
No clinical symptoms were noted in the low dose group while animals of the mid dose group showed black discolored feces during the treatment period from day 13 onwards, probably caused by the test compound. One female animal of the mid dose group showed stilted gait and squatting posture from day 23 up to day 29, another female animal of this group showed squatting posture from day 27 up to study day 29 (end of treatment period). These symptoms however disappeared immediately after the end of treatment. With regard to the findings in the high dose group and acute toxicity testing, it cannot be excluded that these alterations might be substance related in these two animals. Due to the fact that only two animals of this dose group showed this finding and in the absence of any other relevant alterations in the mid dose group, these alterations are not considered as adverse findings as the health status is not affected.
In conclusion, repeated administration of Reaktiv Rot F00-0124 at a dose levels of 50 or 200 mg/kg/d did not cause any adverse substance related alterations. With regard to the present study the 'No Observed Adverse Effect Level' (NOAEL) is 200 mg/kg/d; the 'No Observed Effect Level' (NOEL) is 50 mg/kg/d; and the LOAEL is 800 mg/kg/d.
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
This subchronic study in rats is a GLP and guideline study.
Justification for classification or non-classification
No adverse effects relevant for classification and labelling have been observed in a subacute Oral Toxicity study in rat, according to OECD 407 and GLP.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.